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Summary Infection is a significant contributor to morbidity and mortality in sickle cell disease
(SCD). The sickle gene confers an increased susceptibility to infection, especially to certain
bacterial pathogens, and at the same time infection provokes a cascade of SCD-specific
pathophysiological changes. Historically, infection is a major cause of mortality in SCD, parti-
cularly in children, and it was implicated in 20—50% of deaths in prospective cohort studies over
the last 20 years. Worldwide, it remains the leading cause of death, particularly in less developed
nations. In developed countries, measures to prevent and effectively treat infection have made a
substantial contribution to improvements in survival and quality of life, and are continually being
developed and extended. However, progress continues to lag in less developed countries where
the patterns of morbidity and mortality are less well defined and implementation of preventive
care is poor. This review provides an overview of how SCD increases susceptibility to infections,
the underlying mechanisms for susceptibility to specific pathogens, and how infection modifies
the outcome of SCD. It also highlights the challenges in reducing the global burden of mortality in
SCD.
# 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
Sickle cell disease (SCD) is a collective term for a number of
genetic disorders in which hemoglobin is structurally abnor-
mal, resulting in the episodic formation of sickle-shaped red
blood cells (RBCs) and a wide range of clinical manifesta-
tions. It affects some 12 500 people in the UK and millions
worldwide,1 particularly those of black African and Afro-* Corresponding author.
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doi:10.1016/j.ijid.2009.03.010Caribbean descent, and also those from the Mediterranean,
Middle East, and parts of India.2 The underlying abnormality
is a single nucleotide substitution (GTG for GAG) in the gene
for b-globin on chromosome 11, resulting in the replacement
of a glutamic acid residue with valine on the surface of the
protein (termed HbS).3 In normal adult HbA, two chains of
a-globin and two of b-globin form a tetramer, stabilized by
specific intramolecular points of contact, but without inter-
actions between individual tetramers within the RBC.4 When
the molecule binds or releases oxygen, it undergoes a con-
formational change. In HbS, deoxygenation exposes the
abnormal valine residue on the surface of the molecule,Published by Elsevier Ltd. All rights reserved.
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chains. The resulting polymers align into bundles, causing
distortion of the RBC into a crescent or sickle shape and
reducing flexibility and deformability, which impairs passage
of the cells through narrow blood vessels.3 Sickling can be
precipitated by environmental factors such as hypoxia, low
pH, cold, and dehydration of the RBC, as well as adhesion
molecules and cytokines associated with infections.
Homozygous SS (sickle cell anemia) is generally consid-
ered the most severe form of SCD. Compound heterozygotes,
in whom HbS is combined with a different mutation in the
second b-globin gene, such as HbC, D, OArab or b-thalassemia
(where b-globin synthesis is reduced) can also be affected,
with variable phenotypes. The carrier state (HbAS) does not
cause clinically significant disease (though sickling may occur
under extreme conditions), so carriers are most often una-
ware of their genotype or their sickle gene status, and the
frequency of the gene in some populations is very high: one in
four among Nigerians.5
The clinical manifestations of SCD result from two key
pathological processes: vaso-occlusion and hemolysis. Sickle
cells, along with non-sickled RBCs, leukocytes, and platelets,
form heterocellular aggregates, which adhere to the vascular
endothelium, causing obstruction of the lumen of small blood
vessels. This microcirculatory occlusion leads to acute and
chronic tissue ischemia and infarction, with multisystem
effects, particularly in bone, lungs, brain, kidneys, and
spleen. It is responsible for acute painful episodes and crises
andmany of the long-term complications seen in SCD. Sickled
RBCs are more readily destroyed by the reticulo-endothelial
system, partly as their rigidity makes them more easily
filtered in the spleen and partly due to changes in the
structure of the lipid bilayer (with exposure of anionic phos-
phatidylserine on the RBC surface), which promotes phago-
cytosis.3 With sickle cell anemia (HbSS), this causes a chronic
anemia (a steady state Hb of 6—8 g/dl)6 with a resultant
increase in cardiac output and workload, which produces
cardiomegaly and reduced exercise tolerance. The increased
energy demands due to this and the chronically elevated rate
of hematopoiesis contribute towards poor growth in children,
and individuals are susceptible to any factor exacerbating the
anemia, which can precipitate circulatory failure.7 Intravas-
cular hemolysis also leads to release of free hemoglobin—an
important scavenger of nitric oxide (NO). Reduced levels of
this potent vasodilator and the hyperdynamic circulation
contribute further to vascular damage and occlusion, includ-
ing within larger vessels.4 Despite progress in therapy, SCD
remains a cause of significant morbidity and mortality. Life
expectancy in HbSS from a multicenter study in the USA in
1994 was estimated at 42 formen and 48 for women,8 and 95%
of children survive to adulthood.9
The effect of sickle cell disease on infection
Impaired splenic function
The spleen has a key role in the increased susceptibility to
certain bacterial infections seen in SCD. It functions as a
phagocytic filter, removing old and damaged cells and blood-
borne microorganisms, and also produces antibodies. Blood
from the splenic artery first traverses the white pulp, whichcontains collections of B and T lymphocytes in follicles and
periarteriolar lymphatic sheaths. Activation of these cells by
filtered antigenic material enables initiation and expansion
of a specific acquired immune response. Blood then enters
the splenic cords of the red pulp, where cells flow over a fine
reticular meshwork and pass through fenestrated epithelium
to enter the venous sinuses. This creates a slow flow, enabling
splenic macrophages to remove defective RBCs and bacteria
and to present antigen to lymphocytes.10 Some bacteria can
be recognized directly by macrophages, but many first
require opsonization—coating of the microbial surface by
complement components (especially C3b) or other mole-
cules, which in turn interact with receptors on phagocytes.11
The spleen is the site of synthesis of tuftsin, an immunosti-
mulatory peptide, and properdin, which participates in com-
plement activation.12 Opsonized bacteria are removed
efficiently by macrophages in the spleen or liver, but poorly
opsonized bacteria are only cleared effectively by the
spleen. Such pathogens include encapsulated bacteria, in
particular Streptococcus pneumoniae (pneumococcus) and
Haemophilus influenzae. Their polysaccharide capsule
impedes binding of complement or prevents complement
assembled on the cell wall from interacting with macrophage
receptors.10 Clearance of these bacteria requires anti-poly-
saccharide IgM antibodies, which facilitate phagocytosis
either directly or via deposition of complement over the
capsule itself. A unique B cell population—IgM memory B
cells—resides in the marginal zone of the spleen (adjacent to
the follicles). These cells persist after an initial infection and
rapidly produce antibody on subsequent exposures.13
Individuals with SCD typically suffer from functional hypo-
or asplenism. The sluggish circulation through the spleen,
high rates of O2 extraction, and local acidosis cause deox-
ygenation of HbS, promoting sickling, which leads to conges-
tion and engorgement of the sinusoids with sickled cells. This
can cause diversion of blood via intrasplenic shunts, bypass-
ing the normal filtering mechanisms. Macrophages engulfing
the abnormally shaped cells may become ‘blocked’, impair-
ing their phagocytosis of other particles. Together these
effects produce a hyposplenic state that is initially reversi-
ble, for example if HbS levels are lowered to less than 50% by
blood transfusion, bone marrow transplant, or hydroxyurea
treatment.12 However, over time repeated episodes of sick-
ling and ischemic damage with progressive sclerosis of arter-
ioles lead to multiple infarcts of spleen tissue. Unable to
regenerate, the spleen becomes scarred and atrophied,
culminating in ‘autosplenectomy’, where the organ shrinks
to a small remnant and the individual is rendered effectively
asplenic.14 In HbSS this sequence develops from the age of 6
months to 3 years.12 Hyposplenic and asplenic individuals
lack IgM memory B cells, suggesting a role for the spleen in
their generation or function, and hence they cannot mount a
rapid specific response to encapsulated organisms. Local
infections can readily become systemic and this, in combina-
tion with the loss of the spleen’s filtering function, can permit
overwhelming sepsis to develop. The main pathogen of con-
cern is S. pneumoniae, though severe and systemic infections
with H. influenzae, Neisseria meningitidis, and salmonellae
also occur. Before preventive measures, children with SCD
were 30—600 times more likely to develop invasive pneumo-
coccal disease (IPD), including pneumonia, meningitis, and
septicemia.15 Overwhelming sepsis can develop rapidly with
e4 C. Booth et al.no obvious primary source of infection, resulting in shock,
disseminated intravascular coagulation, adrenal hemor-
rhage, and death within 24 to 48 hours.16 Mortality can reach
35—50% from septicemia and 10% in meningitis. The risk is
confined almost exclusively to young children, with a
reported incidence of 5.8 per 100 in children aged less than
3 years, 1.1 per 100 in those aged 5—9 years, and 0.6 per 100
in those aged over 10 years in the pre-treatment era.17
Curiously, recent reports18—20 from malaria endemic
sub-Saharan Africa suggest that pneumococcal disease
does not contribute significantly to the morbidity and
mortality of children with SCD and it has been argued that
children in this region may be succumbing to other infec-
tions, so established preventive measures used in other
settings may be inappropriate.21 While it is theoretically
conceivable that children affected by SCD in malaria
hyperendemic settings may be at increased risk of death
from other pathogens such as malaria and invasive salmo-
nellosis, poor diagnostic facilities and the high childhood
mortality rates call this assertion into question. Well-
planned longitudinal cohort studies to define the etiologic
agents that predominate in SCD morbidity and mortality in
this region are urgently needed.
Defects in complement activation
A number of other mechanisms for increased susceptibility to
infection in SCD have been explored. Major infections occur
in early infancy when the spleen is still partially functional
and some increased risk persists despite modern prophylactic
measures, suggesting additional immune deficits are pre-
sent.22 Patients also seem predisposed to other infections,
including Escherichia coli urinary tract infection, Myco-
plasma pneumoniae or Chlamydophila pneumoniae respira-
tory infections, and dental infections and cholecystitis
caused by anaerobes. The complement system involves a
large number of plasma proteins that are cleaved sequen-
tially by protease enzymes to generate active fragments.
These function as opsonins or chemoattractants, and the
terminal components can kill some pathogens directly by
creating pores in their membranes. The cascade can be
activated either via the classical pathway, following binding
of IgM or IgG to surface antigens, or the alternative pathway,
in which C3b interacts directly with the pathogen cell sur-
face, then recruiting further downstream components.11
Studies have not consistently demonstrated any deficiencies
in the amount of complement components, but early work
did suggest a reduced functional activity of the alternative
pathway, with lower levels of the active form of factor B (the
first protein recruited by C3b) and impaired opsonization of
yeast in vitro.23 There have been few more recent or large
scale trials to verify these findings, and it seems unwise to
assume that the effect seen in highly simplified, artificial in
vitro experiments would also apply, and be clinically rele-
vant, in vivo. In the absence of extensive studies in normal
populations, it is not known how much the measured activity
of complement varies between healthy individuals. One small
study in 1999 did show an inverse correlation between com-
plement activity and the number of crises suffered by SCD
patients,24 though the mechanism can only be a matter of
speculation. In some studies, reduced leukocyte function in
SCD, particularly neutrophil killing ability, has been shown tocorrelate with clinical severity of the disease.25 However,
this has not been a consistent finding.
Deficiencies in micronutrients
Zinc is known to be important for immune function, so low
levels in SCD have been suggested as a contributory factor in
susceptibility to infection. Zinc deficiency is associated with
lymphopenia, possibly due to activation of the hypothalamo-
pituitary-adrenocortical axis, causing chronic glucocorticoid
production, which stimulates apoptosis of B and T cells in
bone marrow and the thymus.26 It has also been linked with
reduced production of interleukin (IL)-2 (a cytokine needed
for expansion and maintenance of thymocytes and peripheral
T cells), reduced natural killer (NK) cell lytic activity, low
thymulin activity, reduced CD4:CD8 ratio, and impaired Th1
cell function.27 Zinc deficiency may affect 60—70% of SCD
patients. High protein turnover increases requirements,
while hemolysis releases zinc, which is lost via the kidneys
as renal tubular damage impairs reabsorption. At the same
time poor diet and inadequate intestinal absorption could
reduce intake. A study in 21 zinc deficient children suggested
that giving supplements increased IL-2 levels, reduced the
incidence of bacterial infections and cut hospital admis-
sions.27 This was not a fully controlled trial and as changes
were observed over time in a group of subjects, other factors
such as altered susceptibility with age, improvements in diet
or hygiene, or changes in the prevalent environmental patho-
gens may have been responsible for the effects. However, if
such a simple measure as a mineral supplement could
improve quality of life, the issue may warrant further
exploration.
Genetic factors
Despite sharing the same underlying genetic mutation, the
range of severity in the phenotype of SCD is striking, with
some patients disabled by frequent crises and long-term
complications while others live virtually normal lives. Indi-
viduals are also differently predisposed to particular patho-
logical manifestations of the disease. This suggests that the
phenotype is multigenic: since many unlinked genes are
involved in the underlying pathological processes in SCD
(such as destruction of sickled cells or endothelial adhe-
sion), variation in alleles at multiple loci may modify out-
come.3 Polymorphisms in a number of genes involved in the
immune response have been suggested as contributing to
increased susceptibility to infection in SCD. Although
unlinked to the sickle gene, these variants may coinciden-
tally occur with increased frequency in the SCD population.
Particular HLAII subtypes have been shown to be predis-
posing or protecting factors for infectious complications,22
while certain polymorphisms of the FcR receptor (involved
in clearing encapsulated bacteria), mannose-binding lec-
tin, insulin-like growth factor 1 receptor (IGF1-R; involved
in B and T cell recruitment and differentiation), and genes
of the transforming growth factor b (TGFb)/bone morpho-
genetic protein (BMP) pathway have been associated with
an increased risk of bacteremia.28 These studies also high-
light the need for caution in making generalizations about
immune function in SCD, for example complement activa-
tion or neutrophil action, based on experiments using small
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Observed differences may increase individual risk, but
may not be a universal feature.29 Large samples across
multiple racial groups would be needed to distinguish
effects due to SCD per se from those caused by other
unlinked and variable alleles.
Mechanical factors
The pathological effects of SCD can themselves create an
environment supporting infection. Children with SCD are
predisposed to osteomyelitis. The bone marrow space is
expanded to accommodate the increased hematopoiesis
needed to compensate for chronic hemolysis, and oxygen
demand is high. At the same time circulation is sluggish.
Together these factors render bone vulnerable to vaso-occlu-
sive episodes and infarction. Areas of necrotic bone act as
foci for infection, which becomes established via hemato-
genous spread.30 In children unaffected by SCD, Staphylo-
coccus aureus is the predominant pathogen in osteomyelitis.
In SCD, Salmonella is the most common agent, followed by S.
aureus then Gram-negative enteric bacteria.31 In long-term
retrospective reviews from the USA32 and Saudi Arabia,33
Salmonella accounted for 57% and 41.7% of cases of acute
osteomyelitis, respectively. In London, 52.3% of all bacter-
emia over a 15-year period in SCD patients were found to be
due to Salmonella, compared to 0.4% in non-SCD individuals.
Most of these infections were Salmonella typhimurium, a
common food-borne pathogen, and one third resulted in
osteomyelitis.34 It may be that patchy ischemia and infarc-
tion of bowel secondary to microvascular occlusion permits
gut bacteria to invade the intestinal wall and enter the
bloodstream. There does not, however, seem to be any
evidence of increased gastrointestinal carriage of Salmonella
in asymptomatic SCD patients.35
Edwardsiella tarda is another enterobacterium that has
been reported with increased incidence in SCD. Increased gut
permeability and biliary sludging in SCD is likely to be
responsible for this association.36,37
Another consequence of microvascular disease is its asso-
ciation with acute chest syndrome. SCD carries an increased
risk of prolonged and severe respiratory infections due to
Mycoplasma, Chlamydia and other pathogens, particularly in
children prone to pain or microvascular sequestration, such
as those with SC hemoglobinopathy. Several reports in the
literature document an association between respiratory
infections and acute chest syndrome,38,39 but definitive
diagnosis remains a challenge since these are slow growing
fastidious organisms and new molecular diagnostic assays are
yet to be fully validated. Thus the immunopathological
mechanisms leading to this increased risk are not completely
clear.
Finally, SCD patients may be predisposed to certain iatro-
genic infections as a result of therapeutic interventions.
Blood transfusion is commonly used to treat complications,
particularly aplastic crisis or splenic sequestration (when Hb
falls acutely) and acute chest syndrome, priapism, or strokes
(when exchange transfusion is used to reduce the proportion
of HbS).40 Increasingly, chronic transfusion therapy is being
used in children to prevent strokes by keeping HbS levels
below 30%. In developed countries, 5—10% of children may be
involved in a chronic transfusion program at some point intheir lives.2 In general such programs are potentially asso-
ciated with increased risk of blood-borne infections, parti-
cularly hepatitis B and C and HIV. Although all blood products
in developed countries are screened for these viruses, stan-
dards in other countries may not be so exacting, so early
hepatitis B immunization is recommended as a preventive
measure. Other viruses such as cytomegalovirus (CMV) and
parvovirus B19 can also be transmitted. Although not a
problem in immunocompetent individuals, CMV is a signifi-
cant pathogen in the immunocompromised, so children who
are potential candidates for bone marrow transplant should
receive CMV seronegative blood.40 Patients may also be at
risk of catheter-related infections, particularly those on
prolonged courses of parenteral antibiotics or with indwelling
vascular devices for chronic blood transfusion. This has been
reported in adults and seems to be particularly associated
with bone infections.41
The effect of infection on sickle cell disease
Infection has long been recognized as one of the most
common precipitants of crisis in SCD, but only as the mechan-
isms underlying the process of vaso-occlusion have been
better elucidated have the reasons for this become clear.
Vaso-occlusion, initially assumed to be due to passive
mechanical blockage by sickled RBCs, is in fact a complex,
dynamic process involving active interaction between adhe-
sion molecules on the vascular endothelium (e.g., intercel-
lular adhesion molecule 1 (ICAM-1), vascular cell adhesion
molecule-1 (V-CAM1), and a5b3 integrin) and both RBCs and
leukocytes. RBCs attach via surface ligands including a4b1
integrin, basal cell adhesion molecule (BCAM), phosphatidyl-
serine, and sulfated glycans.42 This could contribute directly
to occlusion, but also acts via slowing transit of RBCs through
the microvasculature. The sickling process takes time
because a nucleus of ten deoxy-HbS tetramers must assemble
before rapid polymerization can occur. Usually transit
through the microcirculation is completed before this ‘delay
time’ elapses, so sickling does not take place. If, however,
transit time is prolonged, RBCs equilibrate at a lower O2
tension, leading to greater concentrations of deoxy-HbS and
hence sickling of many cells.3
Leukocyte adhesion may in fact be the initiating event in
vaso-occlusive episodes, as microvascular occlusion occurs in
post-capillary venules—the site of leukocyte attachment for
passage into the extracellular space—rather than pre-capil-
lary arterioles (to be expected from a purely mechanical
effect). Steady state neutrophil count correlates with the
severity of SCD, and treatment with hydroxyurea, which
lowers neutrophil numbers, reduces the frequency of crises,
painful episodes, and hospital admissions.43 Patients with
severe SCD have increased steady state expression of leuko-
cyte adhesion molecules such as Mb2 integrin, L-selectin, and
CD18.44 These observations suggest a central role for leuko-
cytes in the vaso-occlusive process. Narrowing of the vessel
lumen by attached leukocytes may enable the accumulation
of RBCs, platelets, and further leukocytes, with increasing
occlusion. Local hypoxia in areas of poor flow promotes RBC
sickling and propagation of the blockage, culminating in a
crisis. Leukocytes produce cytokines (e.g., tumor necrosis
factor (TNF)-a, IL-1b), which induce the expression of adhe-
sion molecules on the vascular endothelium and can cause
Table 1 Common pathogens associated with infection in
sickle cell anemia with underlying mechanisms for predis-
position
Pathogen Predisposing factors
Encapsulated bacteria
(e.g., Streptococcus
pneumoniae,
Haemophilus influenzae,
Neisseria meningitidis,
Salmonella spp)
Impaired splenic function
Impaired opsonization
Salmonellae Recurrent vaso-occlusion with
intestinal infarct, necrosis
and increased gut permeability
Decreased neutrophil killing
Malaria Decreased deoxyhemoglobin
solubility
Parvovirus Increased red cell turnover
Hepatitis B, C Multiple blood transfusion
Chlamydophila Unknown
Yersinia enterocolitica Iron overload
Mycoplasma Unknown
Edwardsiella tarda Increased intestinal
permeability and biliary
sludging
e6 C. Booth et al.exposure of the underlying extracellular matrix components
to which RBCs also attach.4
During infection with any pathogen, changes occur at a
cellular level, which predispose to crises. Levels of circulat-
ing leukocytes and inflammatory cytokines increase, with
elevated expression of adhesion molecules on both the vas-
cular endothelium and leukocytes themselves. This occurs
locally in infected tissues and systemically. Neutrophils,
basophils, and monocytes attracted to sites of inflammation
produce cytotoxic proteins such as proteases, collagenase,
and elastase and generate reactive O2 radicals, which cause
oxidative damage. This promotes further endothelial activa-
tion and cell adhesion.44 Adrenaline produced in times of
stress can increase the adhesion of laminin to RBC BCAM.3
Local acidosis and hypercapnia in areas of inflammation shift
the Hb oxygen dissociation curve to the right, promoting
unloading of oxygen from Hb and thus increasing sickling.
The sickling process is initially reversible when HbS is
reoxygenated, but dehydration of RBCs increases HbS con-
centration, promoting extensive polymerization and causing
irreversible membrane damage. These poorly deformable
dense cells contribute particularly to vaso-occlusion, adher-
ing readily to leukocytes and endothelium, and also undergo
hemolysis. RBC dehydration occurs due to activation of
cation channels in the cell membrane, causing efflux of K+
and water. The K—Cl co-transporter is constitutively over-
expressed in SCD, but is further activated by low pH. The Ca2+
sensitive K+ efflux Gardos channel is activated by cytokines,
chemokines, and prostaglandin E2 (PGE2), further contribut-
ing to sickling, vaso-occlusion, and hemolysis in infection.3,4
Hemolysis releases free Hb, depleting NO and hence promot-
ing vasoconstriction as previously described. In addition to its
vasodilatory action, NO normally reduces endothelial expres-
sion of adhesion molecules and alters the activation state of
leukocytes. Finally, the release of heme iron causes oxidative
stress, which further stimulates adhesion molecule expres-
sion through action on redox-sensitive transcription factors
(e.g., nuclear factor (NF)-kB).44
In addition, infections can have more non-specific effects
on the host physiological milieu, which increase the risk of
sickling. Fever with water loss due to sweating, anorexia, and
nausea with reduced oral fluid intake, diarrhea, and vomiting
all contribute to dehydration. Renal impairment in SCD
causes poor urinary concentrating ability, so plasma osmo-
larity can rise, promoting RBC dehydration. The stress and
emotional response, accompanied by neural and hormonal
changes, may also play a role.
Effect of specific infections on SCD
Several specific clinical conditions commonly associated with
SCD are caused by particular pathogens (Table 1 ). Some of
these specific agents are briefly discussed in this section. The
mechanisms underlying the increased susceptibility to spe-
cific pathogens are summarized in Table 2.
Parvovirus B19
Parvovirus B19 is a single-strand DNA virus transmitted by
respiratory droplets, occurring in outbreaks particularly in
late winter and early spring.45 It is a common childhood
infection with an incidence of 11.3 per 100 patient-years.
Around 26% of children are seropositive by age 5, rising to47% aged 10, 64% aged 15, and 73% in adulthood.46 In normal
individuals infection is often asymptomatic or gives mild
flu-like symptoms, or may cause erythema infectiosum—
fever and malaise followed by a characteristic ‘slapped
cheek’ rash on the face, progressing to a generalized
maculopapular eruption on the trunk and limbs.45 Its sig-
nificance in SCD and other hemolytic conditions is that it
commonly causes aplastic crisis. Parvovirus B19 specifically
infects erythroid progenitor cells in bone marrow and per-
ipheral blood, using surface P-antigen as a receptor. This
results in temporary cessation of erythropoiesis lasting 7—
10 days. The viral protein NS1 is cytotoxic. It can induce cell
apoptosis, has a direct lytic effect, and can cause cell cycle
arrest in G1 or G2, preventing cell division and differentia-
tion. In healthy individuals, the normal lifespan of a RBC is
120 days, considerably longer than the period of aplasia.
The absence of erythroid precursors in bone marrow (occur-
ring at peak viremia, around 8—10 days after infection)
stimulates an increase in erythropoietin, promoting ener-
getic hematopoiesis once bone marrow recovers. However,
RBCs in SCD have a lifespan of just 5—15 days, so transient
lack of RBC production results in a severe anemia.47 Tran-
sient aplastic crisis occurs in 65—80% of parvovirus B19
infections. Although most children recover within two
weeks, the majority require blood transfusion. Neutropenia
has been reported in 18% and thrombocytopenia in 26.5%,
and other complications include acute splenic or hepatic
sequestration (19%), acute chest syndrome (11.8%), painful
crisis, stroke, nephrotic syndrome, and meningoencephali-
tis. Acute infection can be confirmed by measuring parvo-
virus B19-specific IgM (89% sensitive and 99% specific) or
using PCR to amplify viral DNA. This is important because
the virus is highly contagious, with a secondary attack rate
of over 50% among other household members.45 Siblings
Table 2 Recommended immunization schedule for sickle cell disease
Pneumococcus Meningococcus and Haemophilus
influenzae type b
Influenza
Under 2 years Routinea Routinea Annual
Age 2—5 years (fully immunized) Single dose PPV Booster dose given as the
Hib/MenC vaccine
Annual
Age 2—5 years (unvaccinated or
partially vaccinated)
Two doses of PCV
given 2 months apart,
followed 2 months
later by PPV
Two doses of the Hib/MenC
vaccine given 2 months apart
Annual
Age >5 years (fully vaccinated) Single dose PPV Two doses of the Hib/MenC
given 2 months apart
Annual
Age >5 years (unvaccinated) Single dose PPV Two doses of the Hib/MenC
vaccine given 2 months apart
Annual
Reinforcing immunization PPV every 5 years MenC vaccine every 5 years, Hib
vaccine not currently recommended
Annual
Note: Schedule summarized from Salisbury D, Ramsay M, Noakes K. Immunization against infectious diseases (The Green Book). London:
Department of Health; 2006.78 National childhood immunization in most developing countries does not currently include Hepatitis B, Hib or
meningococcal vaccines. These should be strongly encouraged for children with SCD. In endemic settings consideration should also be given
for immunization with typhoid vaccine.
Hib, Haemophilus influenzae type b; MenC, meningococcus group C; PCV, pneumococcal conjugate vaccine; PPV, pneumococcal poly-
saccharide vaccine.
a Routine UK immunization schedule.
Infection in sickle cell disease e7with SCD should be tested for infection and monitored for
the development of aplastic crisis. After infection immunity
is lifelong, leading to calls for the development of a
vaccine, though aplastic crisis is uncommon after the age
of 15 years.48
Atypical bacteria and acute chest syndrome
The acute chest syndrome (ACS) in SCD is defined as the
combination of chest pain, dyspnea, fever, and pulmonary
infiltrates on chest X-ray.2 It affects 15—43% of patients,
particularly in early childhood, is responsible for 25% of
deaths, and is the second most common cause of hospital
admission.8,49 Various processes can precipitate the condi-
tion, including infection, pulmonary fat embolism from
infarcted bone marrow following an acute skeletal crisis,
hypoventilation (due to pain from a thoracic bony crisis, post-
surgically or from excessive narcotic analgesia), in situ
thrombus formation, or red cell sequestration, though often
the cause is unknown. The unifying end result is sickling and
vaso-occlusion in the small vessels of the lung, causing local
ischemia and sometimes infarction. The ventilation—perfu-
sion mismatch causes systemic hypoxia, predisposing to
further sickling and vascular occlusion in a vicious cycle. If
severe, right heart failure can occur.50 In a large multicenter
study, a cause of ACS was found in 38% of cases. There was
evidence of infection in a third, with 27 different pathogens
isolated, sometimes in combination. The most prevalent
agents were C. pneumoniae (14% of all patients) and Myco-
plasma pneumoniae (9%), the latter more common in younger
patients.51 Although isolation does not confirm causation, the
inflammatory response to lung infection would seem likely to
provoke leukocyte and RBC adhesion and intravascular sick-
ling. Pulmonary fat embolism was the other most frequent
cause identified. Since, as previously described, non-specific
infection can precipitate bone pain crises, it may be thatinfection plays a greater role in ACS than studies can readily
detect.
Malaria
The relationship between malaria and SCD is an intriguing
one. The persistence of the sickle mutation at such high
frequency in African populations in spite of the severity of
SCD has been attributed to the fact that heterozygous
sickle trait confers protection against severe and life-
threatening malaria (in particular cerebral malaria caused
by Plasmodium falciparum). The presence of HbS is asso-
ciated with reduced parasitic invasion of erythrocytes,
impaired multiplication, and accelerated clearance of
parasites by the spleen, as RBC infection produces intra-
cellular hypoxia, provoking sickling and hence splenic fil-
tration of parasitized cells.52 It might be assumed that
homozygous SCD would confer greater resistance to
malaria, however co-existence of the two is associated
with increased mortality and morbidity, and malaria is
the most common precipitating cause of crisis in endemic
countries.53 This mainly reflects the general effects of
systemic infection, including massive release of inflamma-
tory cytokines. The metabolic activity of parasites within
RBCs causes hypoxia, acidosis, and hence sickling.54 Red
cells containing schizonts adhere to the capillary endothe-
lium even in normal individuals, causing obstruction. In SCD
patients, the deleterious effects of this are magnified. The
spleen plays an important role in the control of malaria,
removing damaged and parasitized RBCs from the circula-
tion, ‘pitting’ infected cells (removing parasites and
returning the cells to the circulation intact), and generat-
ing specific B and T cell responses. Splenectomized indivi-
duals with P. falciparum have reduced clearance of
parasitized RBCs, but it is unclear whether they suffer more
severe malarial symptoms.55
e8 C. Booth et al.Malaria causes anemia via a number of mechanisms.56
Infected RBCs undergo hemolysis as merozoites emerge after
multiplying, and non-infected cells can be hemolysed due to
the production of auto-antibodies against RBC surface mole-
cules. Macrophages phagocytose both infected and non-
infected cells. Malaria can cause dyserythropoiesis and sple-
nic sequestration of RBCs (e.g., in young children who have
not undergone autosplenectomy), and recurrent hemolysis
can produce a folate-deficiency anemia. The anemia can be
severe in normal subjects, so is particularly dangerous in SCD.
In a Nigerian study, 66% of children presenting with severe
anemia had malarial infection, and overall mortality was
8.7%.57 Hyperhemolytic crisis refers to a precipitous drop
in Hb associated with jaundice, reticulocytosis, unconju-
gated hyperbilirubinemia, and raised urine urobilinogen. In
one Nigerian center this was the most common type of
anemic crisis in children with SCD. Although malarial para-
sites were detected in the blood of only 17.6%, 70% became
afebrile after transfusion and antimalarials, suggesting a role
for the parasite in the majority of cases.58 Malaria is thus a
significant pathogen in SCD, and long-term prophylaxis has
been shown to lower the incidence of severe anemia and the
number of hospital admissions and crises, as well as reducing
mortality.53
HIV and SCD
Little information is available regarding the impact of coex-
istent HIV infection and SCD. These two conditions no doubt
can present a unique challenge particularly in Africa where
the incidences of both conditions are highest and resources
are scarce. In a recent retrospective study in the USA,
hospital discharges of children with both HIV and SCD over
a 10-year period (1994—2003) were analyzed.59 Children with
both conditions were at increased risk of bacterial infection
and sepsis and also had a longer average stay in hospital.
However, the risk of vaso-occlusive crisis was lower and the
in-patient case—fatality rate was lower than that of children
with HIV infection alone. Increased risk of pneumococcal
infection has also been reported in HIV-infected adults with
SCD.60
Whether SCD attenuates the clinical progression of HIV
disease is an interesting concept, given the reports of high
frequency of long-term non-progressors among patients with
HIV and SCD.61 However, there is no proven mechanistic
explanation for this observation.
Prevention
As illustrated, infection can lead to a range of complications
in SCD, and these are not readily reversed simply by treating
the infection. For this reason, prevention is the key strategy
in management. Interventions in the last 20 years have
dramatically reduced mortality, especially in children, and
the recommendations continue to evolve.
Simple general measures are important in reducing the
risk of infection, though the aim is to ensure as normal a
lifestyle as possible. Meticulous attention to hygiene, parti-
cularly hand-washing, is vital, and to protect against Salmo-
nella, patients are advised to cook food thoroughly,
particularly chicken and eggs, keep items refrigerated,
and avoid contamination.30 Nutritional supplementation with
zinc has been reported to reduce infection risk,27 improvegrowth rates in SCD children, and possibly improve skeletal
and sexual maturation as well as having psychological ben-
efits.62 Early identification of infections is another key area,
enabling prompt initiation of treatment to reduce complica-
tions. Parents are encouraged to monitor their children
closely at home and seek advice if they have a fever or
respiratory symptoms, while maintaining good hydration.
There should be a low threshold for the use of antibiotics
in ill children with SCD, particularly in the presence of chest
signs or symptoms, which may herald ACS. A fever of more
than 38.5 8C is an indication for the empirical use of broad-
spectrum antibiotics such as a third-generation cephalos-
porin, with a macrolide added in potential ACS. Relevant
specimens (blood, urine, sputum, etc.) should be taken for
culture and antibiotics later modified or stopped depending
on the results.2
Antibiotic prophylaxis
As previously discussed, pneumococcus is a major threat to
SCD patients and in unscreened populations the first pre-
sentation of the disease may be with sudden death due to
overwhelming sepsis. The first major breakthrough came in
1986 with the pivotal PROPS trial, which showed that pro-
phylactic oral penicillin reduced the risk of IPD by 84% in
children aged less than 3 years. They reported an incidence of
9.8/100 patient-years, cut to 1.2/100 with prophylaxis.63
This cheap, simple and safe intervention (hypersensitivity
reactions are rare) was rapidly implemented. Current recom-
mendations state that oral penicillin V should be commenced
at 3 months, as levels of protective fetal hemoglobin (which
prevents sickling by inhibiting HbS polymerization) decline
and splenic hypofunction begins to develop. A dose of
62.5 mg twice daily is used for infants less than 1 year,
125 mg twice daily for those aged 1—5 years, and 250 mg
twice daily in those aged above 5 years.2 The duration of
penicillin prophylaxis is controversial. Since the risk of IPD
declines markedly with age, it may be possible to modify or
stop prophylaxis without compromising outcome. The PROP-
SII trial (1995) evaluated the consequences of discontinuing
penicillin at 5 years and found no significant difference in the
incidence of infection between the penicillin and control
groups, suggesting prophylaxis could safely be stopped.64
However, the low overall risk meant the absolute number
of infections was extremely small (two in the penicillin and
four in the placebo group), so any statistically significant
difference would be difficult to detect. Guidelines for asple-
nic individuals still recommend that penicillin prophylaxis be
continued lifelong,65 and this is widely applied to SCD,
although emphasis is placed on treatment in the first 5 years.
Long-term penicillin prophylaxis is not without its pro-
blems. Prolonged or intermittent antibiotic use can promote
the development of resistance, so the recommendation to
continue must represent a balance between the risk to the
individual of pneumococcal infection versus the danger resis-
tant organisms pose to the whole population.66 Blood culture
isolates from the general population in 2001—2 suggested
that 9% of S. pneumoniae in the UK had reduced susceptibility
to penicillin.67 However, in those on prophylaxis, the rates
may be much higher. A survey of children under 5 with SCD in
East London found 20% had asymptomatic nasal carriage of S.
pneumoniae and 25% of these were resistant to penicillin.68
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therapy. One study of children in New York found patients’
(or parents’) own reported compliance with penicillin
prophylaxis was 67.5%, but when measured objectively
with a urine assay the figure was 43.1%. The subgroup of
under 5 s, in whom prophylaxis is most important, had
better adherence (61%).69 Similar results (approximately
50% compliance) have been found in UK children.70 There
are a variety of reasons for poor compliance. Children and
indeed parents often do not understand the reason for
penicillin prophylaxis or the need to take it consistently,
and people are generally reluctant to take any drug in the
long-term, even one whose safety is well established. In a
survey in the USA, the ease of obtaining refills and the
availability of transport predicted compliance.70 Although
prescriptions are free for children aged less than 16 years
in the UK, there is no waiver of the standard National
Health Service (NHS) prescription charge for adults with
SCD, despite their need for lifelong regular drugs—peni-
cillin, folate supplements, and painkillers. Campaigners
delivered a petition to the Government in April 2008 call-
ing for universal free prescriptions in SCD, but this met
with a negative response.71 Even appreciating all of these
contributory factors, interventions to increase compliance
have met with very limited success. Health professionals
should reinforce the reasons for and importance of peni-
cillin prophylaxis at every clinic visit or contact with the
community sickle team and suitable written material
should be supplied where available. Psychological input
may be of benefit in adolescents. Although these would
seem sensible recommendations, there is limited evidence
for their efficacy. One trial involving a formal education
program for parents with intensive home follow-up failed
to increase rates of compliance.72
Vaccination
The other keymedical strategy in the prevention of infection
is vaccination. There are some 90 serotypes of pneumococ-
cal bacteria, which vary in the molecular composition of
their capsule—a strategy for immune evasion. The first
pneumococcal vaccine to be developed consisted of purified
capsular polysaccharide antigens. These produce immunity
via a T cell independent effect, triggering B cells in the
splenic marginal zone to secrete antibody.16 Early uncon-
trolled studies with a vaccine containing 14 antigens sug-
gested a 50% reduction in IPD17 and so these vaccines became
widely accepted, in spite of a lack of thorough controlled
trials in SCD. The current vaccine (Pneumovax, PPS-23)
consists of 23 purified antigens, which should in theory
protect against 75% of invasive and respiratory infections,
with another 14% prevented via cross-protection.73 In one
series, the combination of PPS-23 and penicillin halved rates
of IPD to around 36.5/1000 patient-years, though this still
represents a 10-fold increased risk over the general popula-
tion, with a 100-fold higher risk of mortality.74 The effec-
tiveness of the vaccine diminishes over time, with a booster
required every 5 years. Unfortunately many polysacchar-
ides, especially those from the strains causing most infec-
tions, are either not immunogenic in children under 2 years
or produce only a minimal antibody response with a lack of
immunological memory (so repeat exposure to antigen doesnot produce a booster antibody response).73 This has
prompted the search for an alternative.
The polysaccharide—protein conjugate vaccine (PCV)
complexes capsular polysaccharides to protein carriers
(mutant non-toxic diphtheria toxin), increasing their immu-
nogenicity. Antibodies are produced via a T cell dependent
process, involving T and B cell interactions in germinal cen-
ters. This does induce an effective response in infants under 2
years, with an appropriate memory response after a booster
dose.73 Prevnar1, a 7-valent PCV, was licensed for use in 2000
and includes serotypes responsible for around 70% of infec-
tions in Europe and the USA. Importantly, studies suggested
this vaccine would also cover 77% of isolates with resistance
to penicillin, which would avert prophylaxis failure and may
help to reduce the frequency of such resistant strains.74
Routine immunization of children with PCV-7 began in the
USA in 2000 and in the UK in 2006. Multiple doses are required
for the most effective response: injections are given at 2, 4,
6, and 12 months in the USA and 2, 4, and 13 months in the
UK. This could potentially be a factor limiting full uptake of
the vaccine. There were supply problems in the early years in
the USA, but by 2005 coverage had risen to 82.8%.75 Worry-
ingly, uptake was lower in those of black race and low
household income—precisely those groups likely to be
affected by SCD. In the UK, uptake in the first year was
86%—still somewhat lower than that for other routine child-
hood immunizations.76 Early analysis of the effect in SCD
patients has shown very encouraging results. In Tennessee,
rates of IPD fell by 90.8% in children under 2 years and 93.4%
in children aged less than 5 years. This brought the incidence
to only 6.5 times higher than in unaffected children.15
Another study reported an overall 68% reduction in IPD in
children under 10, including a significant decrease among
unvaccinated children, suggesting a beneficial effect of herd
immunity.77 While vaccination reduces nasopharyngeal car-
riage of pneumococci, there is concern that PCV-7 could
promote replacement with non-vaccine types—altering the
balance of disease-causing strains, or that new pathogenic
strains could emerge in the other serotypes as a result of
transformation and recombination of capsular gene loci.
Careful epidemiological follow-upwill be required tomonitor
such effects. Children with SCD should continue to receive
the PPS-23 vaccine once over 2 years of age, because in
contrast to normal children they remain at high risk from IPD,
especially up to 5 years.73 Penicillin prophylaxis is still
required, in part because all trials have been conducted
using it. It also provides protection against non-PCV-7 pneu-
mococcal strains.
Other vaccines important in children with SCD are Hae-
mophilus influenzae (Hib) and N. meningitidis, hepatitis B,
and influenza. Influenza, as any severe infection, can pre-
cipitate crisis, but may also predispose to bacterial pneu-
monia. A summary of the recommended immunization
program is represented in Table 2.2,78 In addition, children
traveling to endemic areas should be offeredmeningitis A and
C vaccination and malaria prophylaxis.
Conclusions
In this era of effective antibiotics and vaccines, there is a
tendency to see infection as a minor and treatable problem.
In SCD, although these measures have been a huge step
e10 C. Booth et al.forward in preventive care, infection remains a major cause
of morbidity andmortality in the developed and evenmore so
in the developing world. Better understanding of the
mechanisms behind the increased susceptibility to infection
in these patients may in future enable interventions addres-
sing the underlying cause. Early treatment with hydroxyurea
or blood transfusions to lower HbS levels could help preserve
splenic function. However, these therapies are themselves
associated with considerable risks, side effects, and practical
difficulties, making their routine use inappropriate. More
detailed elucidation of the proposed complement activation
and opsonization defect could allow this to be directly
targeted. If specific genetic polymorphisms conferring an
increased risk of infection are identified, testing could help
stratify patients, directing more intensive interventions
towards high-risk groups. Since these breakthroughs probably
represent distant possibilities, the most important step at
present is to improve compliance with current infection
prevention strategies. In developing countries, particularly
Africa, which is home to the vast majority of patients with
SCD and records the highest mortality rates, there is a need
for early diagnosis and improved, structured patient care
programs. Globally, while measures can be taken to improve
understanding and education and maximize convenience for
patients, altering deeply ingrained beliefs and attitudes is a
much more difficult task. The challenge is to prevent both
major infections, which cause considerable pathology in
themselves, and minor infections, which can trigger SCD-
specific effects. Reducing the frequency of crises improves
quality of life andmay help to delay long-term complications,
ultimately extending life expectancy.
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